Download PDF
Neuropediatrics
DOI: 10.1055/s-0044-1788787
Original Article

The Role of Calcitonin Gene-Related Peptide and Amylin in Pediatric Migraine

Hilal Aydin 
1   Department of Pediatrics, Faculty of Medicine, Balikesir University, Balikesir, Turkey
,
Ozgür Baykan 
2   Department of Medical Biochemistry, Faculty of Medicine, Balikesir University, Balikesir, Turkey
› Author Affiliations Funding This work was supported by the Balikesir University Scientific Research Project, 2021/141.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Very few studies have examined the relationship between calcitonin gene-related peptide (CGRP) and amylin levels and the disease in patients with migraine. The purpose of this study was to compare blood CGRP and amylin levels between pediatric migraine patients and healthy controls and the relationship between CGRP and amylin levels and migraine attack frequency and duration.

Methods The study involved two separate groups—control and migraine. Thirty-two patients aged 6 to 18 years presenting to the Balikesir University Medical Faculty pediatric neurology clinic and diagnosed with migraine were included. The control group consisted of 32 patients without migraine presenting to the clinic during the same time frame. The patients' demographic data, personal and family histories, migraine type and frequency, headache severity, basic anthropometric measurements (height, weight, and body mass index), and physical and neurological examination findings were recorded. Migraine patients were classified as ictal if the collection of blood specimens coincided with the attack period and as interictal if this was performed between attacks.

Results No statistically significant differences in mean CGRP or amylin levels were determined between the groups (migraine ictal/interictal) or between the migraine patients (in terms of gender or attack frequency and duration).

Conclusion Elucidating the complex processes involved in the pathogenesis of migraine is important in terms of our ability to develop new treatments and therapeutic strategies. This study aimed to evaluate CGRP and amylin levels in patients with pediatric migraine (in the ictal and interictal periods) compared with those in healthy controls.

Keywords

amylin - CGRP - ictal - interictal - migraine

Ethical Approval

Approval for the study was granted by the local ethical committee prior to commencement (permission no: 2022/57).


Informed Consent

All patients were informed about the study and provided consent forms prior to enrolment.




Publication History

Received: 06 January 2024

Accepted: 14 July 2024

Article published online:
12 August 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 (01) 1-211
    Google Scholar
  • 2 Ailani J, Burch RC, Robbins MS. Board of Directors of the American Headache Society. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 2021; 61 (07) 1021-1039
    CrossrefPubMedGoogle Scholar
  • 3 Førland-Schill A, Berring-Uldum A, Debes NM. Migraine pathophysiology in children and adolescents: a review of the literature. J Child Neurol 2022; 37 (07) 642-651
    CrossrefPubMedGoogle Scholar
  • 4 Ashina M, Terwindt GM, Al-Karagholi MA-M. et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet 2021; 397 (10283): 1496-1504
    CrossrefPubMedGoogle Scholar
  • 5 Pellesi L, Al-Karagholi MA-M, De Icco R. et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open 2021; 4 (08) e2118543
    CrossrefPubMedGoogle Scholar
  • 6 Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 2014; 94 (04) 1099-1142
    CrossrefPubMedGoogle Scholar
  • 7 Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33 (01) 48-56
    CrossrefPubMedGoogle Scholar
  • 8 Cady RK, Vause CV, Ho TW, Bigal ME, Durham PL. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009; 49 (09) 1258-1266
    CrossrefPubMedGoogle Scholar
  • 9 Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia 2019; 39 (12) 1535-1543
    CrossrefPubMedGoogle Scholar
  • 10 Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140 (03) 827-831
    CrossrefPubMedGoogle Scholar
  • 11 Edvinsson L, Grell AS, Warfvinge K. Expression of the CGRP family of neuropeptides and their receptors in the trigeminal ganglion. J Mol Neurosci 2020; 70 (06) 930-944
    CrossrefPubMedGoogle Scholar
  • 12 Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. ScientificWorldJournal 2001; 1: 168-180
    CrossrefPubMedGoogle Scholar
  • 13 Irimia P, Martínez-Valbuena I, Mínguez-Olaondo A. et al. Interictal amylin levels in chronic migraine patients: a case-control study. Cephalalgia 2021; 41 (05) 604-612
    CrossrefPubMedGoogle Scholar
  • 14 Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine-a PET study. J Headache Pain 2014; 15 (01) 84
    CrossrefPubMedGoogle Scholar
  • 15 Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med 2002; 346 (04) 257-270
    CrossrefPubMedGoogle Scholar
  • 16 Messlinger K. Migraine: where and how does the pain originate?. Exp Brain Res 2009; 196 (01) 179-193
    CrossrefPubMedGoogle Scholar
  • 17 Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 2010; 169 (02) 683-696
    CrossrefPubMedGoogle Scholar
  • 18 Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 2010; 30 (10) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 19 Whitehouse F, Kruger DF, Fineman M. et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25 (04) 724-730
    CrossrefPubMedGoogle Scholar
  • 20 Hollander PA, Levy P, Fineman MS. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003; 26 (03) 784-790
    CrossrefPubMedGoogle Scholar
  • 21 Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007; 150 (05) 633-640
    CrossrefPubMedGoogle Scholar
  • 22 Ghanizada H, Al-Karagholi MAM, Walker CS. et al. Amylin analog pramlintide induces migraine-like attacks in patients. Ann Neurol 2021; 89 (06) 1157-1171
    CrossrefPubMedGoogle Scholar
  • 23 Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013; 81 (14) 1191-1196
    CrossrefPubMedGoogle Scholar
  • 24 Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 2018; 19 (01) 53
    CrossrefPubMedGoogle Scholar
  • 25 Rees TA, Hendrikse ER, Hay DL, Walker CS. Beyond CGRP: the calcitonin peptide family as targets for migraine and pain. Br J Pharmacol 2022; 179 (03) 381-399
    CrossrefPubMedGoogle Scholar
  • 26 Yang Y, Ozawa H, Lu H. et al. Immunocytochemical analysis of sex differences in calcitonin gene-related peptide in the rat dorsal root ganglion, with special reference to estrogen and its receptor. Brain Res 1998; 791 (1-2): 35-42
    CrossrefPubMedGoogle Scholar
  • 27 Stucky NL, Gregory E, Winter MK. et al. Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 2011; 51 (05) 674-692
    CrossrefPubMedGoogle Scholar